Limits...
Nitric oxide inhibition strategies

View Article: PubMed Central - PubMed

ABSTRACT

Nitric oxide is involved in many physiologic processes. There are efforts, described elsewhere in this volume, to deliver nitric oxide to tissues as a therapy. Nitric oxide also contributes to pathophysiologic processes. Inhibiting nitric oxide or its production can thus also be of therapeutic benefit. This article addresses such inhibitory strategies.

No MeSH data available.


Synthetic and degradation pathways of nitric.Nitric oxide is synthesized, along with citrulline, from L-arginine by nitric oxide synthase. L-arginine may be proteolyzed to form methylarginines (ADMA and L-NMMA), which in turn inhibit NOS activity by competing with arginine at the active site. Methylarginines are metabolized by dimethyl-arginine-dimethyl-aminohydrolase (DDAH) into citrulline and dimethylarginine. Citrulline can be converted back to arginine by enzymes of the urea cycle [25].NOS: Nitric oxide synthase;DDAH: dimethyl-arginine-dimethyl-aminohydrolase.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4664049&req=5

Figure 0001: Synthetic and degradation pathways of nitric.Nitric oxide is synthesized, along with citrulline, from L-arginine by nitric oxide synthase. L-arginine may be proteolyzed to form methylarginines (ADMA and L-NMMA), which in turn inhibit NOS activity by competing with arginine at the active site. Methylarginines are metabolized by dimethyl-arginine-dimethyl-aminohydrolase (DDAH) into citrulline and dimethylarginine. Citrulline can be converted back to arginine by enzymes of the urea cycle [25].NOS: Nitric oxide synthase;DDAH: dimethyl-arginine-dimethyl-aminohydrolase.

Mentions: There are two endogenous NOS inhibitors (Figure 1). ADMA is a potent, noncompetitive NOS inhibitor, while its congener L-NMMA is a less potent, competitive NOS inhibitor. While ADMA has been shown to contribute to the inflammatory syndrome and endothelial dysfunction seen in shock, its clinical application awaits further investigation.


Nitric oxide inhibition strategies
Synthetic and degradation pathways of nitric.Nitric oxide is synthesized, along with citrulline, from L-arginine by nitric oxide synthase. L-arginine may be proteolyzed to form methylarginines (ADMA and L-NMMA), which in turn inhibit NOS activity by competing with arginine at the active site. Methylarginines are metabolized by dimethyl-arginine-dimethyl-aminohydrolase (DDAH) into citrulline and dimethylarginine. Citrulline can be converted back to arginine by enzymes of the urea cycle [25].NOS: Nitric oxide synthase;DDAH: dimethyl-arginine-dimethyl-aminohydrolase.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4664049&req=5

Figure 0001: Synthetic and degradation pathways of nitric.Nitric oxide is synthesized, along with citrulline, from L-arginine by nitric oxide synthase. L-arginine may be proteolyzed to form methylarginines (ADMA and L-NMMA), which in turn inhibit NOS activity by competing with arginine at the active site. Methylarginines are metabolized by dimethyl-arginine-dimethyl-aminohydrolase (DDAH) into citrulline and dimethylarginine. Citrulline can be converted back to arginine by enzymes of the urea cycle [25].NOS: Nitric oxide synthase;DDAH: dimethyl-arginine-dimethyl-aminohydrolase.
Mentions: There are two endogenous NOS inhibitors (Figure 1). ADMA is a potent, noncompetitive NOS inhibitor, while its congener L-NMMA is a less potent, competitive NOS inhibitor. While ADMA has been shown to contribute to the inflammatory syndrome and endothelial dysfunction seen in shock, its clinical application awaits further investigation.

View Article: PubMed Central - PubMed

ABSTRACT

Nitric oxide is involved in many physiologic processes. There are efforts, described elsewhere in this volume, to deliver nitric oxide to tissues as a therapy. Nitric oxide also contributes to pathophysiologic processes. Inhibiting nitric oxide or its production can thus also be of therapeutic benefit. This article addresses such inhibitory strategies.

No MeSH data available.